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Predictors of mortality in patients initiating antiretroviral 
therapy in Durban, South Africa
Bisola O Ojikutu, Hui Zheng, Rochelle P Walensky, Zhigang Lu, Elena Losina, Janet Giddy, Kenneth A Freedberg
In accordance with the World Health Organization call for 
expanded access to antiretroviral therapy (ART), antiretroviral 
medications have become more widely available to HIV-
infected patients in South Africa who qualify for them (WHO 
stage IV disease or CD4 count <200 cells/µl).  New funding 
through the President’s Emergency Plan for AIDS Relief 
(PEPFAR) and the South African government has led to a 
substantial increase in the number of patients who are able to 
access ART.1  As of April 2007, approximately 300 000 adults 
and children were receiving ART countrywide.2
The factors that have predicted mortality in studies 
evaluating patients prior to initiation of ART include a low 
CD4 cell count, high HIV RNA, mild to severe anaemia, low 
body mass index, elevated aspartate aminotransferase (AST), a 
history of opportunistic infections, and depression.3-6  Additional 
predictors of mortality include older age and advanced disease 
stage at presentation.7  Our objective was to identify predictors 
of mortality in patients initiating ART at the Sinikithemba clinic 
in Durban, South Africa.
McCord Hospital’s Sinikithemba (‘We Give Hope’) Clinic 
has offered ART to patients at cost since 1999.  In 2004 McCord 
Hospital was awarded PEPFAR funding.  Since then, rapid 
scale-up has occurred and over 2 000 patients are receiving 
ART at that site.  As more patients begin treatment, it is 
important to identify factors that predict a higher risk of 
mortality so that they can be more closely monitored.
Methods
We conducted a retrospective cohort study of all patients who 
started ART at the Sinikithemba Clinic from 1 January 1999 
to 29 February 2004.  Patients paid for all medications, except 
for antibiotics for tuberculosis and co-trimoxazole, and for 
laboratory studies, including CD4 count and HIV RNA.  All 
patients initiating ART at Sinikithemba met WHO criteria for 
the use of antiretrovirals in resource-limited settings (WHO 
stage IV or CD4 cell count <200/µl).  The ART regimens 
prescribed at Sinikithemba consisted of three-drug therapy 
using combinations listed by the WHO as approved first-line 
regimens.  Most patients were prescribed non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) in combination with 
two nucleoside reverse transcriptase inhibitors (NRTIs).  The 
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Objective. To identify predictors of mortality in patients 
initiating antiretroviral therapy (ART) in Durban, South 
Africa.  
Design. We conducted a retrospective cohort study analysing 
data on patients who presented to McCord Hospital, Durban, 
and started ART between 1 January 1999 and 29 February 
2004.  We performed univariate and multivariate analysis and 
constructed Kaplan-Meier curves to assess predictors.
Results. Three hundred and nine patients were included. 
Forty-nine (16%) had died by the conclusion of the study.  
In univariate analysis, the strongest predictors of mortality 
were a CD4 cell count <50/µl (hazard ratio (HR) 3.70, 
95% confidence interval (CI) 1.96 - 7.14), a haemoglobin 
concentration ≤8 g/dl (HR 1.23, 95% CI 1.08 - 1.40), a  history 
of oral candidiasis (HR 3.17, 95% CI 1.70 - 5.87) and a history 
of cryptococcal meningitis (HR 2.76, 95% CI 1.80 - 19.2).  A 
CD4 cell count <50/µl (HR 3.08, 95% CI 1.54 - 5.88) and 
a history of oral candidiasis (HR 2.58, 95% CI 1.37 - 4.88) 
remained significant in multivariate analysis.  A history of 
tuberculosis was not a significant predictor of mortality.
Conclusions. Simple clinical and laboratory data 
independently predict mortality and allow for risk 
stratification in patients initiating ART in South Africa. 
Interventions enabling patients to be identified before they 
develop these clinical markers  and earlier initiation of ART 
will help to ensure maximum benefits of therapy.
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analysis also included patients who previously initiated ART 
at sites other than Sinikithemba.  Patients with a history of 
receiving single-dose nevirapine to prevent mother-to-child 
transmission were included in the study. 
Exclusion criteria were: (i) patients whose charts were 
missing or for whom substantial clinical data were missing 
from the file; or (ii) patients who presented to Sinikithemba on 
ART and did not have a pre-ART CD4 cell count and clinical 
history available.
Data collection
Data from paper medical records were reviewed using a 
standardised data collection instrument.  Records were 
reviewed for variables at initial presentation, follow-up and 
death (if applicable).  We collected data in the following 
domains: demographics, ART history, opportunistic infection 
history, clinical, and laboratory.  For patients who died while 
taking ART, date of death and time from diagnosis to death 
were recorded.
A history of opportunistic infections was defined as a history 
reported by the patient to have occurred prior to presentation 
as well as any new diagnosis made prior to the initiation of 
ART.  Because of limited diagnostic capability at the clinic, 
opportunistic infections were noted if there was documented 
clinical evidence or if they were treated empirically with a 
clinical response. 
All chart reviews were conducted by a physician, a registered 
nurse with experience in providing HIV care, or a medical 
student.  A random sample of 40 charts was re-reviewed by a 
second researcher to confirm inter-rater reliability.  Inter-rater 
reliability ranged from 0.9 to 1.00.  Data were double-entered, 
and any errors were corrected.
Statistical analysis
Univariate analysis for association with mortality was 
performed for each of the following variables: age, gender, 
WHO stage, CD4 cell count, weight, employment status, 
haemoglobin concentration and AST as well as history of 
tuberculosis, Pneumocystis jirovecii pneumonia, cryptococcal 
meningitis, Kaposi’s sarcoma, oral candidiasis, toxoplasmosis 
and herpes zoster.  The multivariate model consisted of six 
variables: age, gender, employment status, CD4 cell count, 
history of tuberculosis and history of oral candidiasis.  CD4 
cell count and history of tuberculosis were added on the basis 
of prior studies indicating their significance in predicting 
mortality.  Employment status was added as an indicator of 
socioeconomic status.  Oral candidiasis was included on the 
basis of statistically significant univariate analysis.  Hazard 
ratios (HRs) were derived from univariate and multivariate 
Cox proportional hazards models.  Kaplan-Meier curves 
were stratified by baseline CD4 cell count.  One-year survival 
estimates by CD4 stratum were also determined.  Tests of 
significance were two-sided with a probability cut-off value of 
0.05.
Results
A total of 377 patients over the age of 18 years started ART at 
Sinikithemba during the study period.  Three hundred and 
nine patients were included in the study.  Reasons for exclusion 
were missing charts or charts where substantial clinical 
data was missing (49 patients) and a history of ART prior 
to enrolment at Sinikithemba with no pre-ART clinical data 
available (19 patients). 
Mean age at initial presentation was 38 years (range 24 - 75 
years).  One hundred and seventy-four patients (56%) were 
female.  Fifty-one patients (17%) had a prior history of ART use 
and had pre-ART clinical data available.  Of these, 32 were on 
ART at the time of initial presentation.  The median CD4 cell 
count was 65/µl (25th - 75th quartile = 26 - 138/µl) and the 
mean CD4 cell count 100/µl (standard deviation (SD) 106/µl).  
Fifty-two patients (17%) had an initial CD4 cell count <20/µl, 
76 (26%) a count of 20 - 49/µl, 68 (23%) a count of 50 - 99/µl 
and 102 (34%) a count of ≥100/µl.  The median initial HIV 
RNA was 5.2 log10 copies/ml (25th - 75th quartile = 4.6 - 5.6 
log10 copies/ml) or 158 489 copies/ml, although these results 
were only available for 103 patients (33%).  Sixty per cent of 
patients were in WHO stage IV at presentation (Table I). Forty-
nine patients (16%) had died by the conclusion of the study. 
Univariate analysis revealed that a baseline CD4 cell count 
<50/µl was a significant predictor of mortality (HR 3.70, 95% 
CI 1.96 - 7.14, p<0.0001) (Table II).  Patients who died had a 
mean pre-ART CD4 cell count of 50/µl compared with 109/µl 
for those who were alive at the conclusion of the study.  A 
haemoglobin concentration <8 g/dl was also a significant 
predictor of mortality (HR 1.23, 95% CI 1.08 - 1.40, p=0.0015).  
Initial haemoglobin levels were available for 216 patients in the 
cohort (69%).  This variable was therefore not included in the 
multivariate model.
In univariate analysis, a history of oral candidiasis and 
cryptococcal meningitis also conferred an increased mortality 
risk (HR 3.17, 95% CI 1.70 - 5.87, p=0.0002 and HR 2.76, 95% 
CI 1.07 - 7.10, p=0.03).  Because there were only 12 cases of 
cryptococcal meningitis in the database this was also not 
included in the multivariate model.  Patients with a history 
of tuberculosis (pulmonary or disseminated) were not at a 
significantly increased risk of death (HR 1.16, 95% CI  
0.65 - 2.08, p=0.62) (Table II).  A history of herpes zoster and 
P. jirovecii pneumonia was also not associated with increased 
mortality (HR 0.73, 95% CI 0.31 - 1.73, p=0.48 and HR 1.11, 95% 
CI 0.45 - 2.80, p=0.82).  Only 2 cases of Kaposi’s sarcoma were 
reported, and no cases of toxoplasmosis were documented.
In multivariate analysis, patients with a CD4 cell count  
<50/µl had a 3-fold higher risk of mortality (HR 3.08, 95% CI 
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1.54 - 5.88, p=0.001) and those with a history of oral candidiasis 
a 2.5-fold increased risk (HR 2.58, 95% CI 1.37 - 4.88, p=0.003) 
(Table II).  Age, gender, employment status and history of 
pulmonary or disseminated tuberculosis were not predictive of 
mortality. 
The mean duration of follow-up after ART initiation was 
257 days.  Patient follow-up time was censored due to patient 
drop-out or study conclusion.  If a patient did not return to the 
clinic beyond that date and within 6 months of the conclusion 
of the study, they were designated lost to follow-up. In total, 
23 patients (7.4%) were designated as such.  No difference 
in age, gender, employment status, CD4 count, haemoglobin 
concentration, or presence of opportunistic infections was 
noted between patients who were lost to follow-up and those 
who were not.  Kaplan-Meier curves comparing patients 
within four different initial CD4 cell count strata (<20/µl, 
20 - 49/µl, 50 - 99/µl and ≥100/µl) are shown in Fig. 1.  No 
significant difference was noted in survival between patients 
with an initial CD4 cell count of <20/µl compared with 20 - 
49/µl or in patients with an initial CD4 cell count of 50 - 99/µl 
compared with ≥100/µl.  A significant trend was noted when 
the comparison was made across all CD4 strata (p<0.0001).  
Patients with a CD4 cell count ≥50/µl had significantly lower 
mortality than those with CD4 cell count <50/µl (p<0.0001).  
One-year mortality for patients with a CD4 cell count 20 - 
49/µl was high (0.40, 95% CI 0.24 - 0.55) but not significantly 
different from patients with a CD4 cell count ≤20/µl (0.32, 
95% CI 0.16 - 0.42).  The lowest 1-year mortality was noted for 
patients with a baseline CD4 cell count ≥100/µl (0.10, 95% CI 
0.02 - 0.18). 
Table I. Baseline characteristics of patients who initiated 
antiretroviral therapy in Durban, South Africa, from  
1 January 1999 to 29 February 2004
 
No. of patients   309
Mortality rate (%)   17
Mean age (yrs) (SD)   38 (8.7)
Gender (N (%))*
Male     132 (43)
Female    174 (57)
Employment status (N (%))†
Yes     176 (57)
No     132 (43)
Prior history of antiretroviral  51 (17) 
therapy (N (%)) 
Weight at presentation (median  56.0 (49.0 - 67.0) 
(25th - 75th quartiles)) (kg)   
WHO stage at presentation (N (%))‡
Stage I or II   23 (8)
Stage III    92 (32)
Stage IV   172 (60)
CD4 count§ (median   65 (26 - 138) 
(25th - 75th quartiles)) (cells/µl) 
HIV RNA¶ (median   5.2 (4.6 -5.6) 
(25th - 75th quartiles))  
(log10 copies/ml)          
Baseline laboratory studies (mean (SD))
Haemoglobin (g/dl)  10.0 (2.5)  
ALT (U/l)**   34 (36.7)
AST (U/l)††   46 (47.9)
Missing data (see ‘Methods’ for details): *3 patients; †1 patient; ‡22 patients;  
§11 patients; ¶206 patients; 93 patients; **107 patients; ††113 patients.
SD = standard deviation.
Table II. Variables associated with mortality in a cohort of patients who initiated antiretroviral therapy in Durban, South 
Africa, from 1 January 1999 to 29 February 2004 
       Crude*  Adjusted†
Variable        Group  % dead  HR  (95% CI) p-value  HR (95% CI) p-value
Age (yrs)         ≥40   17            1.39 (0.76 - 2.51)  0.63    1.26 (0.68 - 2.34) 0.46  
       <40              15
Gender       Females  13            0.69 (0.38 - 1.25) 0.11  0.75 (0.40 - 1.38) 0.35  
       Males            20
Employment status      Yes   19            1.62 (0.86 - 3.04) 0.06  1.42 (0.73 - 2.75) 0.30
       No   11 
CD4 count/µl      <50   24            3.73 (1.96 - 7.14) <0.0001    3.09 (1.54 - 5.88) 0.001  
       ≥50   8
Oral candidiasis‡      Yes   22           3.17 (1.70 - 5.87) 0.0002    2.59 (1.37 - 4.88) 0.003
          No   11
Tuberculosis§         Yes               17  1.16 (0.65 - 2.08) 0.62   0.93 (0.51 - 1.71) 0.82
       No   15
*Crude – Cox proportional hazards ratio comparing group 1 v. group 2 in a univariate model with only one risk factor included.
†Adjusted – Cox proportional hazards ratio estimated in a multivariate model including age, gender, employment status, CD4 cell count, oral candidiasis and history of tuberculosis. 
‡135 patients reported a history of oral candidiasis.
§143 patients reported a history of pulmonary and/or disseminated tuberculosis.
HR = Cox proportional hazards ratio; 95% CI = 95% confidence interval.
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Discussion
We sought to determine the factors prior to ART initiation that 
were most predictive of mortality in HIV-infected patients 
after they started ART in Durban, South Africa.  Two factors 
were found to be the strongest predictors of mortality in these 
patients: a CD4 cell count <50/µl and a pre-ART history of oral 
candidiasis.
Mortality differences based on initial CD4 cell count have 
been documented in previous studies in sub-Saharan Africa.8  
This study was consistent with those findings.  Although 
the survival analysis indicates that there is little difference in 
mortality between patients who present with extremely low 
CD4 cell counts (<20/µl) and those who present with counts in 
a slightly higher range (20 - 50/µl), the significant difference in 
survival between patients in the <50/µl group and those in the 
≥50/µl group indicates that immediate interventions may be 
better targeted toward patients with CD4 cell counts <50/µl.
Badri et al. in Cape Town noted that oral candidiasis was a 
significant predictor of mortality in patients who presented for 
care before ART was widely available.9   It is possible that oral 
candidiasis serves as a surrogate marker for the presence of 
undiagnosed opportunistic infection.  Nittayananta et al. found 
a positive association between tuberculosis and the presence 
of oral candidiasis in a cohort of patients from Thailand.10 
Oral candidiasis may also be a marker for more rapid disease 
progression, as is high HIV RNA. Campo et al. noted that high 
HIV RNA was significantly associated with oral candidiasis.11 
Although viral load testing is not widely available in resource-
constrained settings, the presence of oral candidiasis may 
assist clinicians in their assessment of the rapidity of disease 
progression if viral load data are not available.
Tuberculosis is currently the most common cause of AIDS-
related mortality in developing nations.12  While we did not 
find that a pre-ART history of TB predicted mortality after 
starting ART, this study was not specifically powered to detect 
a mortality difference between patients with and without 
a history of TB.  In addition, the lack of association in this 
study may be due to the timing of TB diagnosis.  A history of 
pulmonary TB within the last 2 years is designated as a WHO 
stage III illness in HIV-infected patients.13  TB reported by 
the patient at the initial visit may have occurred more than 2 
years prior to presentation. It is unclear whether or not a more 
distant history of TB infection will have a bearing on mortality. 
This study has several limitations.  CD4 cell counts and 
HIV RNA were not available for all patients because of cost.  
Past history of opportunistic infections may be limited by 
recall bias.  Diagnostic tests that would confirm the presence 
of certain opportunistic infections were limited.  Patients 
who started ART at outside clinics may not have met WHO 
criteria for initiation and may not have been prescribed widely 
accepted regimens.  In addition, follow-up time was relatively 
short, and the retrospective study design limited our ability 
to gather data about factors that may increase the risk of 
mortality, such as lack of social supports and depression.
Over the course of the past year thousands of HIV-infected 
patients in South Africa who met the criteria of the WHO 
and the South African government have started ART.  Since 
the conclusion of this study McCord Hospital’s Sinikithemba 
Clinic has been awarded PEPFAR funding and many more 
patients have enrolled into the clinic’s care and treatment 
programme.  The data from this study will provide important 
baseline parameters against which to measure the expanded 
treatment taking place through the PEPFAR programme.  As 
more patients present for care, it is critical for health care 
providers to be aware of those at highest risk of mortality in 
order to maximise clinical outcomes.  This study demonstrates 
that simple laboratory and clinical data, available to health 
care providers prior to ART initiation, can predict which 
patients are at increased risk of death when they start therapy.  
Interventions enabling more patients to be identified before 
they develop these clinical markers and earlier initiation of 
ART will help ensure maximum benefits of therapy. 
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Fig. 1. Kaplan-Meier curves by CD4 cell count strata for patients initiat-
ing antiretroviral therapy at a clinic in Durban, South Africa, from 
1 January 1999 to 29 February 2004. Circles along each curve indicate pa-
tients censored at each time point.  The numbers below the graph indicate 
the number of patients at risk in each CD4 count stratum at the indicated 
time points.  The number of patients at risk is the number of patients alive 
and followed at each time point.  A significant difference in survival is 
noted for comparisons among the four CD4 cell count strata (p<0.0001).  
See ‘Methods’ for details.
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